Fibrosis status, extrahepatic multimorbidity and all-cause mortality in 53,093 women and 74,377 men with metabolic dysfunction associated steatotic liver disease (MASLD) in UK Biobank
File(s)
Published version
Author(s)
Feng, Qi
Izzi-Engbeaya, Chioma
Manousou, Pinelopi
Woodward, Mark
Type
Journal Article
Abstract
Introduction: People with metabolic-dysfunction associated steatotic liver disease (MASLD) had higher risk of extrahepatic multimorbidity, and fibrosis is the strongest prognostic factor for mortality in MASLD. This study aimed to investigate how fibrosis was associated with multimorbidity and their relationships with all-cause mortality.
Methods: We utilized data from the UK Biobank. MASLD was identified via a Fatty Liver Index ≥ 60 and the presence of cardiometabolic risk factors. The fibrosis-4 (FIB4) score was used to measure liver fibrosis. Multimorbidity was defined as having two or more long-term conditions (LTCs) from a prespecified list of 47 LTCs. Logistic regressions estimated the cross-sectional association between FIB4 scores and multimorbidity prevalence, while Cox models assessed the prospective association between FIB4 scores, multimorbidity and mortality.
Results: We included 127470 participants with MASLD (41.7% female, age 57.4 years, 21.3% with multimorbidity, 2.2% with high FIB4 scores). 14471 deaths were recorded during 13-year follow-up. Compared to low FIB4 scores, high FIB4 scores were associated with 41% higher prevalence of multimorbidity (OR 1.41 (95%CI 1.30-1.54)), and 94% higher all-cause mortality (HR 1.94 (95%CI 1.77-2.13)), while adjusting for multimorbidity reduced the association by 10%, primarily driven by contributions from cardiovascular diseases, extrahepatic cancers, and chronic kidney disease.
Conclusion: FIB4 scores were positively associated with higher multimorbidity and mortality in MASLD patients. Adjustment for multimorbidity reduced 10% the relationship between fibrosis and mortality, with cardiovascular diseases, cancers and chronic kidney disease contributing notably to this reduction. These findings underscore the importance of managing both fibrosis and multimorbidity in MASLD patients.
Methods: We utilized data from the UK Biobank. MASLD was identified via a Fatty Liver Index ≥ 60 and the presence of cardiometabolic risk factors. The fibrosis-4 (FIB4) score was used to measure liver fibrosis. Multimorbidity was defined as having two or more long-term conditions (LTCs) from a prespecified list of 47 LTCs. Logistic regressions estimated the cross-sectional association between FIB4 scores and multimorbidity prevalence, while Cox models assessed the prospective association between FIB4 scores, multimorbidity and mortality.
Results: We included 127470 participants with MASLD (41.7% female, age 57.4 years, 21.3% with multimorbidity, 2.2% with high FIB4 scores). 14471 deaths were recorded during 13-year follow-up. Compared to low FIB4 scores, high FIB4 scores were associated with 41% higher prevalence of multimorbidity (OR 1.41 (95%CI 1.30-1.54)), and 94% higher all-cause mortality (HR 1.94 (95%CI 1.77-2.13)), while adjusting for multimorbidity reduced the association by 10%, primarily driven by contributions from cardiovascular diseases, extrahepatic cancers, and chronic kidney disease.
Conclusion: FIB4 scores were positively associated with higher multimorbidity and mortality in MASLD patients. Adjustment for multimorbidity reduced 10% the relationship between fibrosis and mortality, with cardiovascular diseases, cancers and chronic kidney disease contributing notably to this reduction. These findings underscore the importance of managing both fibrosis and multimorbidity in MASLD patients.
Date Issued
2025-07-31
Date Acceptance
2025-06-09
Citation
BMC Gastroenterology, 2025, 25
ISSN
1471-230X
Publisher
BMC
Journal / Book Title
BMC Gastroenterology
Volume
25
Copyright Statement
© The Author(s) 2025. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Publication Status
Published
Article Number
ARTN 546